> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Momenta, Mylan Sign Deal to Develop 6 Biosimilars
- URL: https://www.fdaweb.com/momenta-mylan-sign-deal-to-develop-6-biosimilars/
- Published: 2016-01-08T12:00:00.000Z
- Updated: 2026-09-15T02:26:08.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5134388

> Momenta Pharmaceuticals and Mylan have entered into a collaboration agreement to develop, manufacture and commercialize six of Momenta’s current biosimilar candidates, including a version of Bristol-Myers Squibb’s Orencia (abatacept), indicated for treating rheumatoid arthritis. Under the agreement, Mylan will make an upfront $45 million cash payment to Momenta, and it is committed to pay up to $200 million in contingent milestone payments. Each company will share equally in the costs and profits with respect to the products. They say they will be jointly responsible for product development, and Mylan will lead worldwide commercialization efforts, with Momenta having an option to co-commercialize in a supporting role for any products in the U.S.